3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Terminated
1
Active not recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
CNS
1
Conditions
Multiple Myeloma
3
Leukemia, Myeloid, Acute
2
Colorectal Neoplasms
2
Stomach Neoplasms
1
Sarcoma, Ewing
1
Rhabdomyosarcoma
1
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Osteosarcoma
1
Neuroblastoma
1
Lymphoma, T-Cell
1
Lymphoma, Mantle-Cell
1
Lymphoma, Large B-Cell, Diffuse
1
Lymphoma, B-Cell
1
Lymphoma
1
Leukemia
1
Gliosarcoma
1
Glioblastoma
1
Esophageal Neoplasms
1
Cholangiocarcinoma
1
Central Nervous System Neoplasms
1
Burkitt Lymphoma
1
Brain Neoplasms
1
Interventions
Temozolomide
28
Radiosurgery
19
Radiotherapy
17
Bevacizumab
12
Magnetic Resonance Spectroscopy
9
Radiation
6
Erlotinib Hydrochloride
6
Carboplatin
6
Topotecan
5
Nivolumab
5
Mental Status and Dementia Tests
5
Irinotecan
5
Capecitabine
5
pembrolizumab
4
dabrafenib
4
Trastuzumab
4
Sunitinib
4
Pemetrexed
4
Ipilimumab
4
Filgrastim
4
Cyclophosphamide
4
Aminolevulinic Acid
4
2,2-dimethyl-N-(6-oxo-6,7-dihydro-5H-dibenzo(b,d)azepin-7-yl)-N'-(2,2,3,3,3-pentafluoropropyl)malonamide
4
cabozantinib
3
Vorinostat
3
TPI-287
3
Specimen Handling
3
Radiotherapy, Intensity-Modulated
3
Methylphenidate
3
Lomustine
3
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Terminated
×
Brain Neoplasms
×
Immunotherapy, Adoptive
×
Clear all
NCT02100891
2025-03-19
STIR
Medical College of Wisconsin
Phase 2
Terminated
15 enrolled
11 charts